Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study.
ADPKD
diuretics
hypertension
polycystic kidney disease
thiazide diuretics
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
27 09 2021
27 09 2021
Historique:
received:
14
02
2020
pubmed:
6
11
2020
medline:
26
11
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin-angiotensin-aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference -0.35 mL/min/1.73 m2 per year [95% confidence interval (CI) -0.83 to -0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5-4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m2 per year [95% CI -0.46 to -0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05-2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50-1.29), P = 0.4]. These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.
Sections du résumé
BACKGROUND
In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin-angiotensin-aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions.
METHODS
We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death.
RESULTS
A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference -0.35 mL/min/1.73 m2 per year [95% confidence interval (CI) -0.83 to -0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5-4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m2 per year [95% CI -0.46 to -0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05-2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50-1.29), P = 0.4].
CONCLUSIONS
These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.
Identifiants
pubmed: 33150452
pii: 5956378
doi: 10.1093/ndt/gfaa150
pmc: PMC8476080
doi:
Substances chimiques
Sodium Chloride Symporter Inhibitors
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1828-1836Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Lancet. 2007 Apr 14;369(9569):1287-1301
pubmed: 17434405
Nat Rev Nephrol. 2009 Apr;5(4):221-8
pubmed: 19322187
Acta Med Scand. 1986;219(4):387-92
pubmed: 3716880
Curr Hypertens Rev. 2018;14(1):39-47
pubmed: 29564978
Kidney Int Rep. 2019 May 16;4(8):1170-1174
pubmed: 31440707
J Am Soc Nephrol. 2015 Jan;26(1):160-72
pubmed: 24904092
Ann Intern Med. 2006 Feb 7;144(3):186-94
pubmed: 16461963
Am J Kidney Dis. 2016 May;67(5):792-810
pubmed: 26530876
Am J Kidney Dis. 2014 Mar;63(3):446-55
pubmed: 24342522
J Am Soc Nephrol. 2016 Mar;27(3):942-51
pubmed: 26150605
Cochrane Database Syst Rev. 2018 Apr 18;4:CD001841
pubmed: 29667175
J Am Soc Nephrol. 2009 Jan;20(1):205-12
pubmed: 18945943
Kidney Int. 2015 Jul;88(1):17-27
pubmed: 25786098
N Engl J Med. 2014 Dec 11;371(24):2267-76
pubmed: 25399731
Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1765-1776
pubmed: 30049849
Kidney Int. 1990 Dec;38(6):1177-80
pubmed: 2074659
JAMA. 2018 Nov 20;320(19):2010-2019
pubmed: 30422235
Acta Med Scand. 1985;217(5):513-8
pubmed: 4025007
N Engl J Med. 2017 Nov 16;377(20):1930-1942
pubmed: 29105594
J Clin Invest. 2017 Sep 1;127(9):3367-3374
pubmed: 28783044
J Int Med Res. 2016 Dec;44(6):1430-1442
pubmed: 27789808
J Hypertens. 2018 Dec;36(12):2284-2309
pubmed: 30379783
J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43
pubmed: 21896142
Clin Exp Nephrol. 2019 Apr;23(4):455-464
pubmed: 30426292
J Hypertens. 2015 Mar;33(3):627-33
pubmed: 25426567
BMC Nephrol. 2018 Jul 3;19(1):157
pubmed: 29970015
Cardiovasc Res. 2001 Aug 15;51(3):372-90
pubmed: 11476728
Nephrol Dial Transplant. 2012 Apr;27(4):1607-13
pubmed: 21873624
J Clin Hypertens (Greenwich). 2008 Jun;10(6):477-84
pubmed: 18550938
J Am Soc Nephrol. 2008 May;19(5):999-1007
pubmed: 18272844
N Engl J Med. 2012 Dec 20;367(25):2407-18
pubmed: 23121377
J Cardiovasc Pharmacol. 2007 Aug;50(2):213-22
pubmed: 17703139